News

Featured News

  • 2021 |
  • 2020 |
  • 2019 |
  • 2018 |
  • 2017 |
  • View All
  • Press Release | July 15, 2020

    Orchard Therapeutics Announces Global License Agreements for Stable Cell Line Technology from GSK

    Read More

    Press Release | July 9, 2020

    ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer

    Read More

    Press Release | July 9, 2020

    Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration

    Read More

    Press Release | July 8, 2020

    Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma

    Read More

    News | July 6, 2020

    Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases

    Read More

    Press Release | July 6, 2020

    Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program

    Read More

    Press Release | June 26, 2020

    Aptinyx to be Added to Russell 2000® Index

    Read More

    Press Release | June 18, 2020

    Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder

    Read More

    News | June 3, 2020

    Biotech Pliant Therapeutics pulls off $144M IPO to advance fibrosis pipeline

    Read More

    Press Release | May 28, 2020

    Palvella Therapeutics Completes $45 Million Series C Financing

    Read More

    Press Release | May 26, 2020

    Freenome Announces Initiation of the PREEMPT CRC Clinical Trial for the Early Detection and Prevention of Colorectal Cancer Using a Multiomics Blood Test

    Read More

    Press Release | May 19, 2020

    HalioDx to Characterize the Immune Contexture of Patients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial

    Read More

    Press Release | May 15, 2020

    New Data from Carisma Therapeutics Uncover Potential of Expedited Pathway for Immunotherapy Development Through CAR Monocytes

    Read More

    Press Release | May 15, 2020

    Orchard Therapeutics Presents New Interim Data from OTL-203 Proof-of-concept Study for MPS-I

    Read More

    News | May 12, 2020

    Merck doubles down on Skyhawk’s tech to drug RNA, promising $600M per autoimmune, metabolic target

    Read More

    News | March 31, 2020

    Latest Penn biotech spinout taking on cancer raises $1.6M from investors

    Read More

    Press Release | March 26, 2020

    First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy

    Read More

    News | March 23, 2020

    First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models

    Read More

    Press Release | March 23, 2020

    Pliant Therapeutics Initiates First-in-Human Clinical Trial of PLN-1474 for the Potential Treatment of Liver Fibrosis

    Read More

    Press Release | March 17, 2020

    ImCheck Therapeutics Expands Leadership Team with Appointment of Hans Henrik Chrois Christensen as Chief Financial Officer and Chief Operating Officer

    Read More